Skip to Content

Xospata Approval History

Reviewed by J.Stewart BPharm. Last updated on Nov 28, 2018.

FDA Approved: Yes (First approved November 28, 2018)
Brand name: Xospata
Generic name: gilteritinib
Dosage form: Tablets
Company: Astellas Pharma US, Inc.
Treatment for: Acute Myeloid Leukemia

Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Hide